Is the Omicron Variant of Coronavirus-19 Infection Really Innocent?

Year 2025, Volume: 5 Issue: 4, 140 - 147, 13.11.2025

İsmail Demir , Elanur Önal Bank , Bekir Baykan , Didem Akkaya , Uygar Yavaş , Sinan Recen , Uğur Doğru , Şebnem Çalık , Oktay Bilgir

https://doi.org/10.56016/dahudermj.1794873

https://izlik.org/JA32AU32RE

Abstract

Background: The Omicron variant of SARS-CoV-2 exhibits higher transmissibility compared to previous variants. This retrospective, single-center study aimed to evaluate the relationship between vaccination status and mortality among patients infected with the Omicron variant.
Methods: This retrospective analysis included 584 patients diagnosed with the Omicron variant of SARS-CoV-2 between January and March 2022 at Bozyaka Training and Research Hospital, Türkiye. Demographic characteristics, comorbidities, laboratory findings, computed tomography (CT) severity scores, vaccination status, and mortality outcomes were assessed. Multivariate logistic regression was used to adjust for potential confounding factors, including age, sex, and comorbidities.
Results: Among the 584 patients, 280 were unvaccinated and 304 vaccinated. Mortality was 21% in unvaccinated patients (mean age 56±17) and 10% in vaccinated patients (mean age 62±15). After adjustment for age and Charlson Comorbidity Index, vaccination remained independently associated with reduced mortality (p<0.05). Unvaccinated patients demonstrated higher inflammatory markers, elevated CT severity scores, and greater ICU admission rates (34% vs. 16%).
Conclusion: Vaccination significantly reduced mortality and lung involvement among patients infected with the Omicron variant. Despite reports of milder disease, Omicron remains clinically significant, particularly in unvaccinated individuals.

Keywords

COVID-19 , Mortality , Omicron , SARS-CoV-2 , Vaccination

Ethical Statement

This study was conducted at Bozyaka Training and Research Hospital and was approved by the ethics committee (approval number 180, dated 27/10/2021).

References

• 1. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–9. doi:10.1172/JCI137244.
• 2. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. [Internet]. 2020 [cited 2025 Nov 10]. Available from: https://www.who.int/directorgeneral/speeches/detail/who-director-general-s-openingremarks-at-the-media-briefing-on-covid-19---11-march-2020
• 3. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450–2. doi:10.1038/s41591-020-0820-9.
• 4. World Health Organization. Tracking SARS-CoV-2 variants. [Internet]. 2025 [cited 2025 Nov 10]. Available from: https://www.who.int/activities/tracking-SARSCoV-2-variants
• 5. Tsui WNT, Hamill V, Noll L, Lu N, Porter EP, Harbidge D, et al. Molecular detection of SARS-CoV-2 and differentiation of Omicron and Delta variant strains. Transbound Emerg Dis. 2022;69(5):e1618–31. doi:10.1111/tbed.14543.
• 6. Sayan M, Arikan A, Isbilen M. Circulating dynamics of SARS-CoV-2 variants between April 2021 and February 2022 in Türkiye. Can J Infect Dis Med Microbiol. 2022;2022:4677720. doi:10.1155/2022/4677720.
• 7. Chen J, Wang R, Gilby NB, Wei GW. Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model. 2022;62(2):412–22. doi:10.1021/acs.jcim.1c01451.
• 8. Tanneti NS, Patel AK, Tan LH, Marques AD, Perera RAPM, Sherrill-Mix S, et al. Comparison of SARS-CoV-2 variants of concern in primary human nasal cultures demonstrates Delta as most cytopathic and Omicron as fastest replicating. mBio. 2024;15(4):e03129-23.doi:10.1128/mbio.03129-23.
• 9. Dixit C, Haleem A, Javaid M. Differentiating the SARS-CoV-2 Omicron (B.1.1.529) variant from other COVID-19 variants of concerns and the common cold. Apollo Medicine. 2022;[Epub ahead of print]. doi:10.4103/am.am_14_22.
• 10. Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. medRxiv. 2021;2021.06.28.21259420. doi:10.1101/2021.06.28.21259420.
• 11. Mohammed I, Nauman A, Paul P, Ganesan S, Chen KH, Jalil SMS, et al. The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Hum Vaccin Immunother. 2022;18(1):2027160. doi:10.1080/21645515.2021.2027160.
• 12. Di Caro A, Cunha F, Petrosillo N, Beeching NJ, Ergonul O, Petersen E, et al. Severe acute respiratory syndrome coronavirus 2 escape mutants and protective immunity from natural infections or immunizations. Clin Microbiol Infect. 2021;27(6):823–6. doi:10.1016/j. cmi.2021.04.014.
• 13. Berlin DA, Gulick RM, Martinez FJ. Severe COVID-19. N Engl J Med. 2020;383(25):2451–60. doi:10.1056/NEJMra2007191.
• 14. Otoshi R, Hagiwara E, Kitayama T, Yamaya T, Higa K, Murohashi K, et al. Clinical characteristics of Japanese patients with moderate to severe COVID-19. J Infect Chemother. 2021;27(6):895–901. doi:10.1016/j.jiac.2021.03.006.
• 15. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–43. doi:10.1001/jamainternmed.2020.0994.
• 16. Toyoshima Y, Nemoto K, Matsumoto S, Nakamura Y, Kiyotani K. SARS-CoV-2 genomic variations associated with mortality rate of COVID-19. J Hum Genet. 2020;65(12):1075–82. doi:10.1038/s10038-020-0808-9.
• 17. Khan SH, Gilani M. Host genome interactions in COVID-19: difficulties in patient management and healthcare policy management. Pak Armed Forces Med J. 2021;71(3):722–3. doi:10.51253/pafmj.v71i3.7380.
• 18. Abdullah F, Myers J, Basu D, Tintinger G, Ueckermann V, Mathebula M, et al. Decreased severity of disease during the first global Omicron variant COVID-19 outbreak in a large hospital in Tshwane, South Africa. Int J Infect Dis. 2022;116:38–42. doi:10.1016/j.ijid.2021.12.357.
• 19. Madhi SA, Kwatra G, Myers JE, Jassat W, Dhar N, Mukendi CK, et al. South African population immunity and severe COVID-19 with Omicron variant. medRxiv. 2021;2021.12.20.21268096. doi:10.1101/2021.12.20.21268096.
• 20. Yıldız Y, Telatar TG, Baykal M, Aykanat Yurtsever B, Yıldız İE. COVID-19 pandemisi döneminde aşı reddinin değerlendirilmesi. Düzce Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi. 2021;11(2):200–5. doi:10.33631/duzcesbed.827142.
• 21. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020;180(10):1345–55. doi:10.1001/jamainternmed.2020.3539.
• 22. Teker AG, Emecen AN, Girgin S, Şimşek-Keskin H, Şiyve N, Sezgin E, et al. Epidemiological characteristics of COVID-19 cases in a university hospital in Türkiye. Klimik Dergisi. 2021;34(1):61–8. doi:10.5152/kd.2021.27.
• 23. Ulloa AC, Buchan SA, Daneman N, Brown KA. Early estimates of SARS-CoV-2 Omicron variant severity based on a matched cohort study, Ontario, Canada. medRxiv. 2022;2021.12.24.21268382. doi:10.1101/2021.12.24.21268382.
• 24. Johnson AG, Amin AB, Ali AR, Hoots B, Cadwell BL, Arora S, et al. COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of Delta and Omicron variant emergence - 25 U.S. jurisdictions, April 4-December 25, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(4):132–8. doi:10.15585/mmwr.mm7104e2.